AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 293 min read$ATR

AptarGroup: Q3 Earnings Snapshot

AptarGroup Inc. (ATR) reported Q3 earnings of $32.6M, or $0.51 per share, and adjusted earnings of $1.52 per share, exceeding analyst expectations of $1.46 per share. Revenue was $1.02B, also above forecasts. The company expects Q4 earnings between $1.39 and $1.47 per share. ATR shares are up 7% YTD and 5% over the past year.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AptarGroup: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ATRBullishMed
01

Why it matters

Traders can use the beat versus estimates and the stated Q4 EPS range to update near-term expectations and assess whether the market will revise full-year forecasts.

02

Market read

Company-specific earnings beat plus forward EPS guidance typically drives immediate repricing and analyst estimate changes.

03

What to watch

The article does not break out segment performance, margin drivers, or cash flow, which can be decisive for whether the beat translates into sustained earnings revisions.

Relevance 8/10Novelty 7/10Timing: after-hours/next-session positioning following the Q3 earnings release

Background

The piece is an earnings snapshot for AptarGroup’s third quarter, including adjusted EPS, revenue, consensus comparisons, and Q4 guidance.

Company-level read

Ticker impact

$ATRBullishHigh confidence
Context

AptarGroup reported Q3 EPS of $1.52 (adjusted) versus $1.46 expected and revenue of $1.02B versus $976.2M, plus Q4 EPS guidance of $1.39 to $1.47.

Expected impact

Shares likely face upward pressure as the market digests the earnings and the specific Q4 EPS range.

Evidence & confidence

The article provides first-hand quarterly results, consensus comparisons, and forward guidance, which are direct inputs to earnings revisions and near-term positioning.

Market effects

Sector

Signals demand and margin resilience for consumer dispensing and drug-delivery components, which can modestly influence sentiment across specialty packaging and dispensing suppliers.

Regional

Limited regional spillover; impact is primarily company-specific.

Global

Low global macro relevance; mostly a single-company earnings and guidance update.

Counterpoint

What could challenge this read

A guidance range that is only modestly above expectations could limit upside if investors were already positioned for a beat.

Key entities

  • company
    AptarGroup Inc.

    Maker of consumer-product dispensing systems; reported Q3 results and provided Q4 EPS guidance.

  • source
    Zacks Investment Research

    Provided the consensus analyst estimates cited in the article.

Read at source← All news

StoryAptarGroup posts Q3 2026 earnings beat with $1.52 adjusted EPS and 6% revenue growth

Also covered by

4 outlets

Related articles

OCT 31
$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

finance.yahoo.com7 min
OCT 30
$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.

finance.yahoo.com2 min
OCT 29
$ATRMedAI 8/10

AptarGroup Sales Rise 6%; Adjusted EPS Reaches $1.52

AptarGroup reported Q3 2026 sales of $1.02B, up 6% YoY, with adjusted EPS at $1.52. Core sales rose 5%, while net income fell to $32.6M from $127.9M YoY due to a $60.4M after-tax impact from deconsolidating its Russian subsidiary. CEO Gael Touya highlighted priorities including customer relationships and innovation.

tradingview.com1 min